Inventiva S.A. - American Depos (IVA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Momentum 3.5/10 is below the 5.0 floor at $5.04 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0).
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a... Read more
Sell if holding. Momentum 3.5/10 is below the 5.0 floor at $5.04 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 130d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Inventiva S.A. - American Depos
Latest news
- Inventiva Recruits Axel-Sven Malkomes As New CFO — benzinga Apr 22, 2026 neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.5/10 is below the 5.0 floor at $5.04 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $4.72. Score 5.3/10, moderate confidence.
Take-profit target: $5.94 (+18.3% upside). Prior stop was $4.72. Stop-loss: $4.72.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0); Negative momentum; Value-trap signals (3/5): Revenue declining (-89.9% YoY), Margin compression (op margin -6710.7%), Negative free cash flow.
Inventiva S.A. - American Depos trades at a P/E of N/A (forward -6.0). TrendMatrix value score: 5.0/10. Verdict: Sell.
16 analysts cover IVA with a consensus score of 4.4/5. Average price target: $16.
What does Inventiva S.A. - American Depos do?Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies...
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.